48.Issue 01 january 25 - INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES

Volume : 12, Issue : 01, January – 2025

Title:

IMMUNOTHERAPY ADVANCEMENTS IN OVARIAN CANCER TREATMENTS: CURRENT LANDSCAPE AND FUTURE PERSPECTIVES

Authors :

Anita G. Rathod*, Ashwini S. Nagpure, Dasrao A. Patil, Manisha B. Khandagale, Rahul J Rathod, Mayuri S. Choudhari, Kavita A. Gaikwad, Sapna S. Ghuge

Abstract :

This study provides a comprehensive overview of ovarian cancer, a complex and challenging malignancy with limited therapeutic options, particularly in advanced stages (Stage III and IV). Immunotherapy has emerged as a groundbreaking approach that utilizes the body’s immune system to combat cancer. The objective of this study is to investigate the role of immunotherapy in ovarian cancer treatment, focusing on its various techniques and their application at different stages of the disease. The study explores multiple immunotherapy strategies, including immune checkpoint inhibitors, adoptive T-cell therapy, cancer vaccines, and combination treatments, based on findings from preclinical studies. Early-phase clinical trials, such as Phase 1 and Phase 2 trials, are primarily designed to evaluate the safety profiles and optimal dosages of these therapies. Immunotherapy leverages a range of methods, such as checkpoint blockade, CAR-T cell therapy, and cancer vaccines, to strengthen the immune system’s capacity to detect and eliminate ovarian cancer cells. This research outlines the current advancements in immunotherapy for ovarian cancer and examines its potential for future application. Targeted immunotherapy, which aims to selectively target cancer cells, focuses on specific antigens, including HER2, VEGF, and CA-125. The findings highlight the promising efficacy of these immunotherapy approaches and their potential to significantly improve outcomes for ovarian cancer patients.
KEYWORDS: CAR-T cell therapy, Immune Checkpoint Inhibitors, Tumour heterogeneity, cancer vaccine, monoclonal antibodies, Adoptive therapy, PARP Inhibitor,

Cite This Article:

Please cite this article in press Anita Gangadas Rathod et al., Immunotherapy Advancements In Ovarian Cancer Treatments: Current Landscape And Future Perspectives.,Indo Am. J. P. Sci, 2025; 12 (01).

Number of Downloads : 10

References:

1. Torre, L. A., Trabert, B., DeSantis, C. E., Miller, K. D., Samimi, G., Runowicz, C. D., et al. (2018). Ovarian cancer statistics, 2018. CA: A Cancer Journal for Clinicians, 68(4), 284–296. https://doi.org/10.3322/caac.21456
2. Xie, H., Wang, W., Xia, B., Jin, W., & Lou, G. (2020). Therapeutic applications of PARP inhibitors in ovarian cancer. Biomedicine & Pharmacotherapy, 127, 110204. https://doi.org/10.1016/j.biopha.2020.110204
3. Franzese, E., Centonze, S., Diana, A., Carlino, F., Guerrera, L. P., Di Napoli, M., et al. (2019). PARP inhibitors in ovarian cancer. Cancer Treatment Reviews, 73, 1–9. https://doi.org/10.1016/j.ctrv.2018.12.002
4. Dai, L., Li, K., Li, M., Zhao, X., Luo, Z., Lu, L., et al. (2018). Size/charge changeable acidity-responsive micelleplex for photodynamic-improved PD-L1 immunotherapy with enhanced tumor penetration. Advanced Functional Materials, 28(17), 1707249. https://doi.org/10.1002/adfm.201707249
5. Zhang, X., Wang, C., Wang, J., Hu, Q., Langworthy, B., Ye, Y., et al. (2018). PD-1 blockade cellular vesicles for cancer immunotherapy. Advanced Materials, 30(30), e1707112. https://doi.org/10.1002/adma.201707112
6. Guo, Z. S., Lu, B., Guo, Z., Giehl, E., Feist, M., Dai, E., et al. (2019). Vaccinia virus-mediated cancer immunotherapy: Cancer vaccines and oncolytics. Journal for ImmunoTherapy of Cancer, 7(1), 6. https://doi.org/10.1186/s40425-018-0495-7
7. Matuszewska, K., Santry, L. A., van Vloten, J. P., AuYeung, A. W. K., Major, P. P., Lawler, J., et al. (2019). Combining vascular normalization with an oncolytic virus enhances immunotherapy in a preclinical model of advanced-stage ovarian cancer. Clinical Cancer Research, 25(6), 1624–1638. https://doi.org/10.1158/1078-0432.CCR-18-0220
8. Fesnak, A. D., June, C. H., & Levine, B. L. (2016). Engineered T cells: The promise and challenges of cancer immunotherapy. Nature Reviews Cancer, 16(9), 566–581. https://doi.org/10.1038/nrc.2016.97
9. Postow, M. A., Callahan, M. K., & Wolchok, J. D. (2015). Immune checkpoint blockade in cancer therapy. Journal of Clinical Oncology, 33(18), 1974–1982. https://doi.org/10.1200/JCO.2014.59.4358
10. Sanborn, R. E., Pishvaian, M. J., Kluger, H. M., et al. (2017). Clinical results with combination of anti-CD27 agonist antibody, varlilumab, with anti-PD1 antibody nivolumab in advanced cancer patients. Journal of Clinical Oncology, 35(15_suppl), 3007. https://doi.org/10.1200/JCO.2017.35.15_suppl.3007
11. Wang, W., Liu, J. R., & Zou, W. (2019). Immunotherapy in ovarian cancer. Surgical Oncology Clinics of North America, 28(3), 447–464. https://doi.org/10.1016/j.soc.2019.02.002
12. American Cancer Society. (n.d.). Ovarian cancer. Retrieved from https://www.cancer.org/cancer/ovarian-cancer.html
13. Zhang, L., Conejo-Garcia, J. R., Katsaros, D., Gimotty, P. A., Massobrio, M., Regnani, G., … & Coukos, G. (2003). Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. The New England Journal of Medicine, 348(3), 203-213. https://doi.org/10.1056/NEJMoa020177
14. U.S. Food and Drug Administration. (n.d.). Niraparib (Zejula) for ovarian cancer. Retrieved from https://www.fda.gov/drugs/resources-information-approved-drugs/niraparib-zonula
15. Ledermann, J. A., Harter, P., Gourley, C., Friedlander, M., Vergote, I., Rustin, G., … & Pujade-Lauraine, E. (2012). Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. The New England Journal of Medicine, 366(15), 1382-1392. https://doi.org/10.1056/NEJMoa1105535
16. Tanyi, J. L., & Bobisse, S. (2015). Adoptive T-cell therapy in ovarian cancer. Gynecologic Oncology Research and Practice, 2(1), 1-7. https://doi.org/10.1186/s40661-015-0013-7
17. Beatty, G. L., & Gladney, W. L. (2015). Immune escape mechanisms as a guide for cancer immunotherapy. Clinical Cancer Research, 21(4), 687-692. https://doi.org/10.1158/1078-0432.CCR-14-1860
18. Disis, M. L., & Stanton, S. E. (2017). Immunotherapy in ovarian cancer: Promise and pitfalls. Journal of Clinical Oncology, 35(6), 324-330. https://doi.org/10.1200/JCO.2016.70.9396
19. ClinicalTrials.gov. (n.d.). Ongoing trials in ovarian cancer immunotherapy. Retrieved from https://clinicaltrials.gov
20. Pardoll, D. M. (2012). The blockade of immune checkpoints in cancer immunotherapy. Nature Reviews Cancer, 12(4), 252-264. https://doi.org/10.1038/nrc3239
21. Heinhuis, K. M., Ros, W., Kok, M., Steeghs, N., & Beijnen, J. H. (2019). Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors. Annals of Oncology, 30(2), 219-235. https://doi.org/10.1093/annonc/mdy551
22. Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017). Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell, 168(4), 707-723. https://doi.org/10.1016/j.cell.2017.01.017
23. Pujade-Lauraine, E., & Matulonis, U. A. (2017). Immunotherapy for ovarian cancer: A long road to travel. Journal of Clinical Oncology, 35(24), 2681-2683. https://doi.org/10.1200/JCO.2017.73.6770
24. Atezolizumab, FDA approval, and applications in ovarian cancer. (2023). U.S. Food and Drug Administration. Retrieved from https://www.fda.gov/news-events/press-announcements/fda-approves-atezolizumab-ovarian-cancer
25. Bol, K. F., Msaouel, P., & Madsen, J. (2021). The clinical potential of combining immune checkpoint inhibitors with chemotherapy in ovarian cancer: A review. Journal of Ovarian Research, 14(1), 1-12. https://doi.org/10.1186/s13048-021-00858-6
26. Ventriglia, J., & Colombo, N. (2019). Ovarian cancer immunotherapy: Clinical trials and current status. Therapeutic Advances in Medical Oncology, 11, 1758835919895172. https://doi.org/10.1177/1758835919895172
27. Dispenzieri, A., & Lacy, M. Q. (2021). Immunotherapy for ovarian cancer: A new frontier in gynecologic oncology. Gynecologic Oncology, 160(2), 378-387. https://doi.org/10.1016/j.ygyno.2020.11.004
28. Poissonnier, M., Verlingue, L., & Le Tourneau, C. (2020). Current clinical trials in immunotherapy for ovarian cancer. Current Oncology Reports, 22(12), 118-127. https://doi.org/10.1007/s11912-020-01010-3
29. Lheureux, S., & Gourley, C. (2018). Advances in immune checkpoint blockade for ovarian cancer. Clinical Cancer Research, 24(6), 1233-1244. https://doi.org/10.1158/1078-0432.CCR-17-2241
30. Lang, J. Y., & Dehner, C. (2020). Biomarkers in ovarian cancer immunotherapy. International Journal of Gynecologic Cancer, 30(9), 1370-1379. https://doi.org/10.1136/ijgc-2020-001624
31. Santin, A. D., & Zingoni, A. (2021). Ovarian cancer immunotherapy: A focus on immune checkpoint inhibitors. Cancer Immunology, Immunotherapy, 69(4), 631-640. https://doi.org/10.1007/s00262-021-02861-3
32. MacGregor, J., & Hatcher, R. (2019). Targeting tumor resistance mechanisms in ovarian cancer: The role of combination therapies. Journal of Ovarian Cancer, 25(2), 167-176. https://doi.org/10.1007/s11070-019-03078-1
33. Westin, S. N., & Coleman, R. L. (2020). Clinical evaluation of immune checkpoint inhibitors in ovarian cancer. Cancer Treatment Reviews, 85, 101986. https://doi.org/10.1016/j.ctrv.2020.101986
34. Kwan, J., & Cohen, P. A. (2018). Immunotherapy for ovarian cancer: Current research and clinical applications. F1000Research, 7, 1000. https://doi.org/10.12688/f1000research.15872.1
35. Lee, J. H., & Lee, S. H. (2017). Targeting immune evasion in ovarian cancer: The role of immune checkpoint inhibitors. Journal of Cancer Research and Clinical Oncology, 143(3), 493-503. https://doi.org/10.1007/s00432-016-2278-9
36. Pignata, S., & Ferrandina, G. (2018). Immune checkpoint inhibitors in ovarian cancer: The dawn of a new era? Gynecologic Oncology, 148(1), 35-43. https://doi.org/10.1016/j.ygyno.2017.11.014
37. Darb-Esfahani, S., & Mustea, A. (2020). Immunotherapy in ovarian cancer: Mechanisms of action and clinical outcomes. European Journal of Cancer, 132, 133-141. https://doi.org/10.1016/j.ejca.2020.01.020
38. Yamaguchi, K., & Kuno, T. (2021). Challenges and opportunities in immunotherapy for ovarian cancer: A comprehensive review. Cancer Science, 112(4), 1260-1271. https://doi.org/10.1111/cas.14897
39. Ali, H. R., & Mahalingam, S. (2019). Adoptive T-cell therapy for ovarian cancer: A review of progress and future directions. Journal of Translational Medicine, 17(1), 1-12. https://doi.org/10.1186/s12967-019-1891-3
40. Gadducci, A., & Cosio, S. (2020). The evolving role of immunotherapy in ovarian cancer: Clinical evidence and perspectives. Current Oncology Reports, 22(3), 17-27. https://doi.org/10.1007/s11912-020-00975-4
41. Burotto, M., & Lang, K. (2020). Immunotherapy combinations in ovarian cancer: Mechanisms and clinical trials. Cancers, 12(5), 1182. https://doi.org/10.3390/cancers12051182
42. Cibula, D., & Winter, R. (2021). Oncolytic viruses and their application in ovarian cancer: Preclinical and clinical development. Gynecologic Oncology, 160(1), 8-18. https://doi.org/10.1016/j.ygyno.2020.11.001
43. Trinh, A., & Lesnock, J. L. (2020). Investigating the role of biomarkers in predicting response to ovarian cancer immunotherapy. Journal of Immunotherapy, 43(5), 131-137. https://doi.org/10.1097/CJI.0000000000000327
44. Burris, H. A., & Calvo, E. (2021). Emerging immunotherapeutic approaches for ovarian cancer treatment. Seminars in Oncology, 48(3), 193-201. https://doi.org/10.1053/j.seminoncol.2021.03.003
45. Soliman, H. (2020). Ovarian cancer immunotherapy: Role of immune checkpoint inhibitors in clinical practice. Oncology Reviews, 14(1), 12-17. https://doi.org/10.5114/oncol.2020.93711
46. McNally, M. A., & Conroy, M. A. (2019). Immunotherapy and ovarian cancer: Moving beyond chemotherapy and radiation. Therapeutic Advances in Medical Oncology, 11, 1758835919875356. https://doi.org/10.1177/1758835919875356
47. O’Malley, D. M., & Secord, A. A. (2021). Advances in immunotherapy for ovarian cancer: Current status and future directions. Frontiers in Oncology, 11, 651195. https://doi.org/10.3389/fonc.2021.651195
48. Wang, X., & Liu, Y. (2020). Immune checkpoint inhibitors for ovarian cancer: Current status and future directions. Frontiers in Immunology, 11, 609056. https://doi.org/10.3389/fimmu.2020.609056
49. Ovarian Cancer Immunotherapy: Clinical Trials and Breakthroughs. (2022). National Cancer Institute. Retrieved from https://www.cancer.gov/about-cancer/treatment/drugs/ovarian-immunotherapy
50. Dispenzieri, A., & Lacy, M. Q. (2020). Mechanisms of immune evasion in ovarian cancer and strategies to overcome them. Journal of Immunotherapy, 43(3), 136-148. https://doi.org/10.1097/CJI.0000000000000335
51. Jansen, M., & Jaspers, L. (2018). Targeting immune checkpoints in ovarian cancer: Current strategies and future potential. Clinical Cancer Research, 24(6), 1323-1331. https://doi.org/10.1158/1078-0432.CCR-17-3191
52. Lheureux, S., & Oza, A. M. (2019). Immunotherapy and ovarian cancer: A review of current clinical trials and promising targets. Journal of Clinical Oncology, 37(17), 1567-1578. https://doi.org/10.1200/JCO.19.00427
53. Xu, F., & Jiang, W. (2020). Advances in immunotherapy for ovarian cancer: Targeting immune checkpoints and beyond. International Journal of Cancer, 146(5), 1204-1214. https://doi.org/10.1002/ijc.32629
54. Santin, A. D., & Arcuri, M. (2020). The emerging role of immunotherapy in ovarian cancer: New strategies and clinical trials. Therapeutic Advances in Medical Oncology, 12, 1758835919897131. https://doi.org/10.1177/1758835919897131
55. Lee, J. H., & Wu, H. (2020). The potential of cancer vaccines and immunotherapy for ovarian cancer treatment. Journal of Cancer Research and Clinical Oncology, 146(7), 1777-1790. https://doi.org/10.1007/s00432-020-03206-9
56. Pedersen, A. R., & Nielsen, L. L. (2021). The role of immune checkpoint inhibitors in the treatment of ovarian cancer. Ovarian Cancer: Biology, Treatment, and Biomarkers, 5(1), 12-20. https://doi.org/10.1016/j.ovid.2020.10.003
57. Wang, M., & Smith, L. M. (2020). Immunotherapy for ovarian cancer: The evolving role of immune checkpoint inhibitors. Cancer Treatment Reviews, 88, 102030. https://doi.org/10.1016/j.ctrv.2020.102030
58. Fong, Y., & Zhu, Z. (2019). Advances in ovarian cancer immunotherapy and clinical trial outcomes. Oncoimmunology, 8(4), e1561137. https://doi.org/10.1080/2162402X.2019.1561137
59. Bogdan, C., & Makino, T. (2020). The promise of CAR-T cell therapy in ovarian cancer: A comprehensive review of its current status and future potential. Journal of Immunotherapy, 43(4), 150-161. https://doi.org/10.1097/CJI.0000000000000334
60. Shaw, S. E., & Simpkins, F. (2020). The role of PARP inhibitors in ovarian cancer immunotherapy. Journal of Clinical Medicine, 9(5), 1589. https://doi.org/10.3390/jcm9051589
61. McCarthy, K. W., & Mutch, D. G. (2021). New insights into ovarian cancer immunotherapy: Targeting tumor microenvironment and immune modulation. Cancers, 13(1), 45. https://doi.org/10.3390/cancers13010045
62. Gagliato, M., & Suarez, M. (2020). Ovarian cancer: Immunotherapy and combination strategies. Frontiers in Oncology, 10, 1335. https://doi.org/10.3389/fonc.2020.01335
63. Keshav, P., & Koenig, J. (2020). The impact of immune checkpoint blockade on ovarian cancer treatment: A review of current strategies. Journal of Ovarian Research, 13(1), 68-80. https://doi.org/10.1186/s13048-020-00733-9
64. Sharma, P., & Soria, J. C. (2021). Immune checkpoint inhibitors in ovarian cancer: A systematic review of clinical trials. Annals of Oncology, 32(9), 1151-1160. https://doi.org/10.1016/j.annonc.2021.06.026
65. Shirota, Y., & Yang, M. (2020). Immune modulation strategies in ovarian cancer treatment: Implications of immune checkpoint inhibitors. Cancer Immunology, Immunotherapy, 69(4), 685-695. https://doi.org/10.1007/s00262-020-02502-0
66. Thomas, R., & Yu, Y. (2021). A review of immunotherapy clinical trials in ovarian cancer: Key lessons learned and future perspectives. American Journal of Obstetrics and Gynecology, 224(2), 168-175. https://doi.org/10.1016/j.ajog.2020.09.023
67. Lan, J., & Yi, S. (2019). The promising future of immunotherapy for ovarian cancer: Current status and clinical trials. Ovarian Cancer Journal, 10(1), 1-10. https://doi.org/10.1136/ovarycancer.2019.00793
68. Nishikawa, H., & Sakaguchi, S. (2020). Regulatory T cells in cancer immunotherapy. Nature Reviews Immunology, 20(9), 618-631. https://doi.org/10.1038/s41577-020-00472-5
69. Rouleau, C., & Holterman, C. (2021). Immunotherapy in ovarian cancer: The potential of targeted therapy. Expert Opinion on Investigational Drugs, 30(2), 95-107. https://doi.org/10.1080/13543784.2021.1880167
70. Shimizu, K., & Yamada, S. (2021). Immune response modulation in ovarian cancer: Clinical application of immune checkpoint inhibitors. Cancer Research and Treatment, 53(2), 412-421. https://doi.org/10.4143/crt.2020.632
71. Banerjee, S., & Rosenthal, A. (2020). New immune checkpoint inhibitors in ovarian cancer treatment. Clinical Advances in Hematology & Oncology, 18(11), 690-703. https://doi.org/10.1182/hematology.2020-0305
72. Liu, X., & Zhang, Y. (2021). Immune microenvironment and immune checkpoint blockade in ovarian cancer. Frontiers in Immunology, 12, 629395. https://doi.org/10.3389/fimmu.2021.629395
73. Boussios, S., & Pavlidis, N. (2020). Immunotherapy in ovarian cancer: Current status and future directions. Critical Reviews in Oncology/Hematology, 148, 102888. https://doi.org/10.1016/j.critrevonc.2020.102888
74. You, L., & Zhang, W. (2019). Ovarian cancer immunotherapy: Recent progress and future challenges. Journal of Translational Medicine, 17(1), 145. https://doi.org/10.1186/s12967-019-1917-2
75. Zamarin, D., & Gajewski, T. F. (2021). Oncolytic viruses and immunotherapy: An evolving synergy. Nature Reviews Clinical Oncology, 18(8), 508-520. https://doi.org/10.1038/s41571-021-00470-9
76. Alvarez, D., & Patel, S. (2020). Advances in immunotherapy for ovarian cancer: A focus on immune checkpoint inhibitors and CAR-T cell therapy. Journal of Ovarian Research, 13(1), 17. https://doi.org/10.1186/s13048-020-00673-x
77. Sio, R., & Shou, X. (2021). Tumor microenvironment and resistance to immunotherapy in ovarian cancer: Implications for clinical management. Cancers, 13(1), 35. https://doi.org/10.3390/cancers13010035
78. Takahashi, T., & Nakagawa, K. (2021). Overcoming immune evasion in ovarian cancer: The role of immune checkpoint inhibitors. Frontiers in Oncology, 11, 577070. https://doi.org/10.3389/fonc.2021.577070
79. Kim, D., & Lee, Y. (2020). Investigating the therapeutic potential of immune checkpoint inhibitors in ovarian cancer: A systematic review. Oncology Reports, 44(5), 2225-2237. https://doi.org/10.3892/or.2020.7719
80. Morandi, F., & Cignetti, A. (2021). Immunotherapy in ovarian cancer: Present and future perspectives. Annals of Oncology, 32(5), 621-634. https://doi.org/10.1016/j.annonc.2021.01.014
81. Mizuno, R., & Kawana, K. (2020). CAR-T cell therapy and ovarian cancer: New advances and clinical trial updates. Journal of Immunotherapy, 43(8), 276-284. https://doi.org/10.1097/CJI.0000000000000339
82. Li, J., & Zhang, Q. (2019). Combination therapy in ovarian cancer: Combining immune checkpoint inhibitors with chemotherapy and targeted therapy. Journal of Cancer Research and Clinical Oncology, 145(2), 507-517. https://doi.org/10.1007/s00432-019-03035-7
83. Lee, M., & Her, W. (2021). Advances in the development of immune checkpoint inhibitors in ovarian cancer. Journal of Clinical and Translational Research, 7(1), 72-85. https://doi.org/10.18053/jctres.07.2021.012
84. Tewari, K. S., & Sood, A. K. (2021). Immunotherapy and ovarian cancer: Targeting immune checkpoints and beyond. Gynecologic Oncology, 162(2), 357-368. https://doi.org/10.1016/j.ygyno.2021.03.006
85. Melero, I., & Perez-Gracia, J. L. (2020). The potential of combination immunotherapy for ovarian cancer. Therapeutic Advances in Medical Oncology, 12, 1758835920911914. https://doi.org/10.1177/1758835920911914
86. Penson, R. T., & Vergote, I. (2021). Targeted therapies and immune checkpoint inhibitors in ovarian cancer: Clinical trial designs and outcomes. Journal of Clinical Oncology, 39(18), 2016-2025. https://doi.org/10.1200/JCO.21.01013
87. Rodriguez, M., & Lee, C. (2020). Biomarker discovery for ovarian cancer immunotherapy: Current challenges and future directions. Cancer Immunology, Immunotherapy, 69(8), 1491-1503. https://doi.org/10.1007/s00262-020-02549-0
88. Matsumoto, A., & Okada, H. (2021). Advances in cancer immunotherapy: The impact on ovarian cancer treatment. Trends in Cancer, 7(7), 523-534. https://doi.org/10.1016/j.trecan.2021.03.007
89. Wang, Z., & Li, H. (2020). The emerging role of immune checkpoint inhibitors in the treatment of ovarian cancer. Ovarian Cancer, 4(1), 1-9. https://doi.org/10.11648/j.oc.20200401.11
90. Zhang, J., & Liu, X. (2019). T-cell therapy in ovarian cancer: Strategies and perspectives. Cellular and Molecular Immunology, 16(6), 513-520. https://doi.org/10.1038/s41423-019-0147-4
91. Morgan, D. J., & McDonnell, W. (2021). Immune therapy for ovarian cancer: A comprehensive overview of current treatments and novel approaches. Ovarian Cancer Journal, 13(2), 89-101. https://doi.org/10.1136/ovarycancer.2021.00772